AR and prostate cancer: In this context, TMPRSS2 is induced by androgens through a distal androgen receptor (AR) binding enhancer51, resulting in AR-induced expression of a TMPRSS2-ERG (ETS-related gene) fusion gene conferring prostate cancer pathogenicity52.